# Clinical Trial to Assess Efficacy, Tolerability of Rising Doses of Clodronate in Painful Knee Osteoarthritis Patients

> **NCT06263517** · PHASE2,PHASE3 · UNKNOWN · sponsor: **SPA Società Prodotti Antibiotici S.p.A.** · enrollment: 296 (estimated)

## Conditions studied

- Osteoarthritis of Knee

## Interventions

- **DRUG:** Clodronate
- **DRUG:** Clodronate
- **DRUG:** Clodronate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06263517
- **Lead sponsor:** SPA Società Prodotti Antibiotici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-10-12
- **Primary completion:** 2025-07
- **Final completion:** 2025-10
- **Target enrollment:** 296 (ESTIMATED)
- **Last updated:** 2024-02-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06263517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06263517, "Clinical Trial to Assess Efficacy, Tolerability of Rising Doses of Clodronate in Painful Knee Osteoarthritis Patients". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT06263517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*